{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T07:15:05Z","timestamp":1783149305109,"version":"3.54.6"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001332","name":"Council for Scientific and Industrial Research, South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001412","name":"Council of Scientific & Industrial Research","doi-asserted-by":"publisher","award":["09\/007(13660\/2022-EMR-I"],"award-info":[{"award-number":["09\/007(13660\/2022-EMR-I"]}],"id":[{"id":"10.13039\/501100001412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bioorg.2026.109948","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:02:25Z","timestamp":1777964545000},"page":"109948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Design, computational profiling, synthesis and biological evaluation of novel 1,2,4-triazole based derivatives as antioxidant and potent p53-MDM2 inhibitors"],"prefix":"10.1016","volume":"178","author":[{"given":"Dushyant D.","family":"Kotadiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooja S.","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchi","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharmesh A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth S.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanu","family":"Priya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.bioorg.2026.109948_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109948_bb0010","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2174\/09298665113209990056","article-title":"Protein-protein interactions and prediction: a comprehensive overview","volume":"21","author":"Sowmya","year":"2014","journal-title":"Protein Pept. Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109948_bb0015","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.cbpa.2005.03.001","article-title":"Protein\u2013protein interactions and cancer: small molecules going in for the kill","volume":"9","author":"Arkin","year":"2005","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109948_bb0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/ijms21010013","article-title":"How the other half lives: what p53 does when it is not being a transcription factor","volume":"21","author":"Ho","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109948_bb0025","article-title":"Mitochondrial death functions of p53","volume":"1","author":"Marchenko","year":"2014","journal-title":"Mol. Cell. Oncol."},{"issue":"12","key":"10.1016\/j.bioorg.2026.109948_bb0030","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.3390\/ijms17122003","article-title":"Molecular mechanisms of p53 deregulation in Cancer: an overview in multiple myeloma","volume":"17","author":"Herrero","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.bioorg.2026.109948_bb0035","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026211","article-title":"Attenuating the p53 pathway in human cancers: many means to the same end","volume":"6","author":"Wasylishen","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"6381","key":"10.1016\/j.bioorg.2026.109948_bb0040","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/358080a0","article-title":"Amplification of a gene encoding a p53-associated protein in human sarcomas","volume":"358","author":"Oliner","year":"1992","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109948_bb0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbamcr.2013.05.022","article-title":"The role of ubiquitin modification in the regulation of p53","volume":"1843","author":"Hock","year":"2014","journal-title":"Biochim. Biophys. Acta - Mol. Cell Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109948_bb0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/ijms21010261","article-title":"Regulation of the p53 family proteins by the ubiquitin proteasomal pathway","volume":"21","author":"Bang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109948_bb0055","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1021\/acsomega.1c04726","article-title":"P53: stability from the Ubiquitin\u2013Proteasome System and specific 26S proteasome inhibitors","volume":"7","author":"do Patrocinio","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.109948_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130394","article-title":"A concise review on MDM2 inhibitors and recent progress in radiopharmaceutical development for imaging MDM2 expression in tumors with PET or SPECT","volume":"129","author":"Siriki","year":"2025","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2026.109948_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104834","article-title":"Bridging the gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer","volume":"214","author":"Di Grazia","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109948_bb0070","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev.pharmtox.48.113006.094723","article-title":"Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for Cancer therapy","volume":"49","author":"Shangary","year":"2009","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"5659","key":"10.1016\/j.bioorg.2026.109948_bb0075","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1126\/science.1092472","article-title":"In vivo activation of the p53 pathway by small-molecule antagonists of MDM2","volume":"303","author":"Vassilev","year":"2004","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bioorg.2026.109948_bb0080","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1021\/jm049137g","article-title":"Discovery and Cocrystal structure of Benzodiazepinedione HDM2 antagonists that activate p53 in cells","volume":"48","author":"Grasberger","year":"2005","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109948_bb0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.molmed.2006.11.002","article-title":"MDM2 inhibitors for cancer therapy","volume":"13","author":"Vassilev","year":"2007","journal-title":"Trends Mol. Med."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109948_bb0090","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1073\/pnas.0708917105","article-title":"Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition","volume":"105","author":"Shangary","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"17","key":"10.1016\/j.bioorg.2026.109948_bb0095","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.1158\/1078-0432.CCR-07-5136","article-title":"Targeting the MDM2-p53 interaction for Cancer therapy","volume":"14","author":"Shangary","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109948_bb0100","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1158\/1535-7163.MCT-05-0199","article-title":"Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo","volume":"5","author":"Koblish","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109948_bb0105","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-022-01314-3","article-title":"Targeting p53\u2013MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials","volume":"15","author":"Zhu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109948_bb0110","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/nrd1523","article-title":"The role of the medicinal chemist in drug discovery \u2014 then and now","volume":"3","author":"Lombardino","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109948_bb0115","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2174\/1389450116666150309115922","article-title":"Heterocyclic scaffolds: centrality in anticancer drug development","volume":"16","author":"Ali","year":"2015","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bioorg.2026.109948_bb0120","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejmech.2015.12.017","article-title":"Pyrrole: an emerging scaffold for construction of valuable therapeutic agents","volume":"110","author":"Gholap","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109948_bb0125","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ejmech.2018.08.002","article-title":"Pyrrole: an insight into recent pharmacological advances with structure activity relationship","volume":"157","author":"Ahmad","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109948_bb0130","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.ejmech.2005.02.013","article-title":"Synthesis, characterization and antimicrobial activity of some substituted 1,2,3-triazoles","volume":"40","author":"Holla","year":"2005","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109948_bb0135","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1021\/jm00163a054","article-title":"Growth inhibition and induction of cellular differentiation of human myeloid leukemia cells in culture by carbamoyl congeners of ribavirin","volume":"33","author":"Sanghvi","year":"1990","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109948_bb0140","doi-asserted-by":"crossref","DOI":"10.2478\/v10007-008-0024-1","article-title":"Synthesis and evaluation of analgesic, anti-inflammatory and ulcerogenic activities of some triazolo- and 2-pyrazolyl-pyrido[2,3-d]-pyrimidines","volume":"58","author":"Hafez","year":"2008","journal-title":"Acta Pharm."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109948_bb0145","doi-asserted-by":"crossref","DOI":"10.1515\/HC.2000.6.5.421","article-title":"Synthesis and antibacterial activity of some heterocyclic \u03b2-enamino ester derivatives with 1,2,3-triazole","volume":"6","author":"Chen","year":"2000","journal-title":"Heterocycl. Commun."},{"issue":"4","key":"10.1016\/j.bioorg.2026.109948_bb0150","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1023\/B:RUJO.0000036090.61432.18","article-title":"Synthesis of 4-Aryl-5-nitro-1,2,3-triazoles","volume":"40","author":"Sheremet","year":"2004","journal-title":"Russ. J. Org. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109948_bb0155","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.bmc.2015.03.049","article-title":"Novel thiazolo[3,2-b]-1,2,4-triazoles derived from naproxen with analgesic\/anti-inflammatory properties: synthesis, biological evaluation and molecular modeling studies","volume":"23","author":"Sarigol","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.109948_bb0160","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1021\/jm801343r","article-title":"Identification of a metabolically stable Triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice","volume":"52","author":"Gujjar","year":"2009","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109948_bb0165","first-page":"254","article-title":"Synthesis of some quinoline-2(1H)- one and 1, 2, 4 - triazolo [ 4 , 3 -a ] quinoline derivatives as potent anticonvulsants","volume":"10","author":"Guan","year":"2007","journal-title":"J. Pharm. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109948_bb0170","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.bmcl.2009.01.090","article-title":"The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: establishing the pharmacophore","volume":"19","author":"Johns","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"48","key":"10.1016\/j.bioorg.2026.109948_bb0175","first-page":"1229","article-title":"Pyrrolo [2, 3-d][1,2,3] triazoles as potential antineoplastic agents","volume":"6","author":"Passannanti","year":"1998","journal-title":"Heterocycles"},{"issue":"7","key":"10.1016\/j.bioorg.2026.109948_bb0180","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0014-827X(02)01248-X","article-title":"Synthesis and preliminary anticancer activity of new 1,4-dihydro-3-(3-hydroxy-2-naphthyl)-4-substituted-5H-1,2,4-triazoline-5-thiones","volume":"57","author":"Duran","year":"2002","journal-title":"Il Farmaco"},{"issue":"1","key":"10.1016\/j.bioorg.2026.109948_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/14756360903524304","article-title":"Pharmacological significance of triazole scaffold","volume":"26","author":"Kharb","year":"2011","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109948_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111700","article-title":"1,2,3-Triazole-containing hybrids as potential anticancer agents: current developments, action mechanisms and structure-activity relationships","volume":"183","author":"Xu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.109948_bb0195","first-page":"789","article-title":"A novel series of Benzimidazole-Triazole-Tetrazole compounds: synthesis, structural analysis, and cytotoxic activity against MCF-7 cells","author":"Zaki","year":"2025","journal-title":"Egypt. J. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109948_bb0200","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3998\/ark.5550190.0007.904","article-title":"The chemistry of mercapto- and thione- substituted 1,2,4-triazoles and their utility in heterocyclic synthesis","volume":"2006","author":"Shaker","year":"2006","journal-title":"Arkivoc"},{"issue":"13","key":"10.1016\/j.bioorg.2026.109948_bb0205","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1080\/00397911.2019.1608450","article-title":"Synthesis, biological evaluation and computational studies of fused acridine containing 1,2,4-triazole derivatives as anticancer agents","volume":"49","author":"Mahanti","year":"2019","journal-title":"Synth. Commun."},{"key":"10.1016\/j.bioorg.2026.109948_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104369","article-title":"Novel 1,2,4-triazole derivatives as apoptotic inducers targeting p53: synthesis and antiproliferative activity","volume":"105","author":"Gomaa","year":"2020","journal-title":"Bioorg. Chem."},{"issue":"14","key":"10.1016\/j.bioorg.2026.109948_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26146572","article-title":"New 1,2,4-Triazole derivatives with a N-Mannich Base structure based on a 4,6-Dimethylpyridine scaffold as anticancer agents: design, synthesis, biological evaluation, and molecular modeling","volume":"26","author":"\u015awi\u0105tek","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.109948_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.130000","article-title":"Design, synthesis and biological evaluation of novel 5-(4-chlorophenyl)-4-phenyl-4H-1,2,4-triazole-3-thiols as an anticancer agent","volume":"1231","author":"Patel","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109948_bb0225","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.2147\/DDDT.S307113","article-title":"Imidazole as a promising medicinal scaffold: current status and future direction","volume":"15","author":"Alghamdi","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109948_bb0230","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.13005\/bpj\/2696","article-title":"Imidazole scaffold: a review of synthetic strategies and therapeutic action","volume":"16","author":"Tripathi","year":"2023","journal-title":"Biomed. Pharmacol. J."},{"issue":"28","key":"10.1016\/j.bioorg.2026.109948_bb0235","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.2174\/1568026621666210527103225","article-title":"Imidazole scaffold based compounds in the development of therapeutic drugs","volume":"21","author":"Hu","year":"2021","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109948_bb0240","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22239","article-title":"In vitro cytotoxic and in vivo antitumoral activities of some aminomethyl derivatives of 2,4-dihydro-3H-1,2,4-triazole-3-thiones\u2014evaluation of their acetylcholinesterase and carbonic anhydrase enzymes inhibition profiles","volume":"33","author":"Timur","year":"2019","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"1\u20133","key":"10.1016\/j.bioorg.2026.109948_bb0245","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejphar.2012.06.023","article-title":"Effect of 4-(4-bromophenyl)-5-(3-chlorophenyl)-2,4-dihydro-3H-1,2,4-triazole-3-thione on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model","volume":"690","author":"Luszczki","year":"2012","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109948_bb0250","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1590\/S0103-50532012000500010","article-title":"Synthesis, urease inhibition, antioxidant and antibacterial studies of some 4-amino-5-aryl-3H-1,2,4-triazole-3-thiones and their 3,6-disubstituted 1,2,4-triazolo[3,4-b]1,3,4-thiadiazole derivatives","volume":"23","author":"Hanif","year":"2012","journal-title":"J. Braz. Chem. Soc."},{"issue":"11","key":"10.1016\/j.bioorg.2026.109948_bb0255","doi-asserted-by":"crossref","first-page":"4716","DOI":"10.1016\/j.ejmech.2009.05.030","article-title":"Synthesis of substituted-phenyl-1,2,4-triazol-3-thione analogues with modified d-glucopyranosyl residues and their antiproliferative activities","volume":"44","author":"Li","year":"2009","journal-title":"Eur. J. Med. Chem."},{"issue":"13","key":"10.1016\/j.bioorg.2026.109948_bb0260","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1002\/slct.202100025","article-title":"Design, synthesis and biological evaluation of novel 5-Phenyl-5-(thiophen-2-yl)-4 H -1,2,4-triazole-3-thiols as an anticancer agent","volume":"6","author":"Patel","year":"2021","journal-title":"ChemistrySelect"},{"key":"10.1016\/j.bioorg.2026.109948_bb0265","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jfluchem.2013.07.017","article-title":"Total synthesis of \u03b3-trifluoromethylated analogs of goniothalamin and their derivatives","volume":"155","author":"Chen","year":"2013","journal-title":"J. Fluor. Chem."},{"key":"10.1016\/j.bioorg.2026.109948_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112652","article-title":"An insight on medicinal attributes of 1,2,4-triazoles","volume":"205","author":"Aggarwal","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.109948_bb0275","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3390\/molecules29020346","article-title":"Aromatase inhibitors as a promising direction for the search for new anticancer drugs","volume":"29","author":"Janowska","year":"2024","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.bioorg.2026.109948_bb0280","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00204-020-02689-3","article-title":"Antioxidants and antioxidant methods: an updated overview","volume":"94","author":"Gulcin","year":"2020","journal-title":"Arch. Toxicol."},{"issue":"3","key":"10.1016\/j.bioorg.2026.109948_bb0285","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3109\/14756366.2014.943203","article-title":"Synthesis and antioxidant activities of some new triheterocyclic compounds containing benzimidazole, thiophene, and 1,2,4-triazole rings","volume":"30","author":"Mente\u015fe","year":"2015","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.109948_bb0290","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1007\/s00204-023-03562-9","article-title":"Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging","volume":"97","author":"Jomova","year":"2023","journal-title":"Arch. Toxicol."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109948_bb0295","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/biomedicines13051149","article-title":"Redox balance in Cancer in the context of tumor prevention and treatment","volume":"13","author":"Sutkowy","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.bioorg.2026.109948_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133946","article-title":"Benzimidazole-hydrazone derivatives: synthesis, in vitro anticancer, antimicrobial, antioxidant activities, in silico DFT and ADMET studies","volume":"1270","author":"I\u015eIK","year":"2022","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109948_bb0305","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.24996\/ijs.2025.66.5.2","article-title":"Synthesis, identification of some new 1, 2, 4-triazole derivatives from 2-(4-methoxyphenyl)-3-ethyl acetate \u22124(3H) - quinazolinone and evaluation anti-oxidant activity","author":"Saeed","year":"2025","journal-title":"Iraqi J. Sci."},{"key":"10.1016\/j.bioorg.2026.109948_bb0310","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7324\/JAPS.2015.50620","article-title":"Evaluation as antioxidant agents of 1,2,4-triazole derivatives: effects of essential functional groups","author":"Cetin","year":"2015","journal-title":"J. Appl. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109948_bb0315","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13065-023-00961-y","article-title":"Design, synthesis, molecular docking and biological evaluation of new carbazole derivatives as anticancer, and antioxidant agents","volume":"17","author":"\u00c7apan","year":"2023","journal-title":"BMC Chem."},{"key":"10.1016\/j.bioorg.2026.109948_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.134437","article-title":"Design, synthesis, characterization, antioxidant, antiproliferative activity and molecular docking studies of new transition metal complexes of 1,2,4-triazole as combretastatin A-4 analogues","volume":"1274","author":"Jawad","year":"2023","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2026.109948_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2025.108492","article-title":"Discovery of newer 1,3,4-Oxadiazole clubbed Isoindoline-1,3-dione derivatives as potential anticancer agents: design, machine learning, synthesis, molecular docking, ADMET, DFT and MD simulation","volume":"118","author":"Matore","year":"2025","journal-title":"Comput. Biol. Chem."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109948_bb0330","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1021\/ja310377d","article-title":"Structural insights into a unique inhibitor binding pocket in kinesin spindle protein","volume":"135","author":"Ulaganathan","year":"2013","journal-title":"J. Am. Chem. Soc."},{"issue":"6","key":"10.1016\/j.bioorg.2026.109948_bb0335","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22255","article-title":"Biphenylsulfonamides as effective MMP-2 inhibitors with promising antileukemic efficacy: synthesis, in vitro biological evaluation, molecular docking, and MD simulation analysis","volume":"85","author":"Baidya","year":"2024","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2026.109948_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2020.128360","article-title":"Synthesis, biological evaluation, molecular docking, molecular dynamics and DFT studies of quinoline-fluoroproline amide hybrids","volume":"1217","author":"Ganesan","year":"2020","journal-title":"J. Mol. Struct."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109948_bb0345","doi-asserted-by":"crossref","first-page":"34687","DOI":"10.1038\/s41598-025-10589-8","article-title":"In silico identification of prospective p53-MDM2 inhibitors from ASINEX database using a comprehensive molecular modelling approach","volume":"15","author":"Kotadiya","year":"2025","journal-title":"Sci. Rep."},{"issue":"20","key":"10.1016\/j.bioorg.2026.109948_bb0350","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1016\/j.bmcl.2018.08.027","article-title":"In vitro and in vivo characterization of a novel, highly potent p53-MDM2 inhibitor","volume":"28","author":"Vaupel","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.bioorg.2026.109948_bb0355","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s00894-014-2191-y","article-title":"Combined structure- and ligand-based pharmacophore modeling and molecular dynamics simulation studies to identify selective inhibitors of MMP-8","volume":"20","author":"Kalva","year":"2014","journal-title":"J. Mol. Model."},{"issue":"5\u20136","key":"10.1016\/j.bioorg.2026.109948_bb0360","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1080\/10799893.2019.1585453","article-title":"Molecular docking, 3D-QSAR, molecular dynamics, synthesis and anticancer activity of tyrosine kinase 2 (TYK 2) inhibitors","volume":"38","author":"Itteboina","year":"2018","journal-title":"J. Recept. Signal Transduct."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109948_bb0365","doi-asserted-by":"crossref","DOI":"10.1093\/biomethods\/bpab026","article-title":"Structure-based discovery of selective CYP17A1 inhibitors for castration-resistant prostate cancer treatment","volume":"7","author":"Omoboyowa","year":"2022","journal-title":"Biol. Methods Protoc."},{"issue":"9","key":"10.1016\/j.bioorg.2026.109948_bb0370","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.1080\/07391102.2022.2062786","article-title":"A molecular dynamics perspective into estrogen receptor inhibition by selective flavonoids as alternative therapeutic options","volume":"41","author":"Sinyani","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2026.109948_bb0375","doi-asserted-by":"crossref","DOI":"10.2174\/012210299X310595240626104426","article-title":"Evaluation of 3, 3\u2019-Disubstituted Oxindoles derivatives as a potential anti-cancer tyrosine kinase inhibitors-molecular docking and ADME studies","volume":"02","author":"Kaur","year":"2024","journal-title":"Curr. Indian Sci."},{"issue":"1","key":"10.1016\/j.bioorg.2026.109948_bb0380","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13065-018-0469-3","article-title":"Pyridyl thiosemicarbazide: synthesis, crystal structure, DFT\/B3LYP, molecular docking studies and its biological investigations","volume":"12","author":"Abu-Melha","year":"2018","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.bioorg.2026.109948_bb0385","article-title":"Design, synthesis of new 2,4-thiazolidinediones: in-silico, in-vivo anti-diabetic and anti-inflammatory evaluation","volume":"11","author":"Gharge","year":"2024","journal-title":"Eur. J. Med. Chem. Rep."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826004840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T06:16:10Z","timestamp":1783145770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826004840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":77,"alternative-id":["S0045206826004840"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109948","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, computational profiling, synthesis and biological evaluation of novel 1,2,4-triazole based derivatives as antioxidant and potent p53-MDM2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.109948","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109948"}}